CLRB News and Press, Cellectar Biosciences Inc. From 02/14/20

Are These The Best Stocks To Trade Before The End Of February 2020? It goes without saying that investing in penny stocks comes with a certain level of risk. But at the same time, these cheap stocks can often generate substantial returns in a short period of time. Over the years, plenty of...

The following slide deck was published by Cellectar Biosciences, Inc. in conjunction with this Read more ...

FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Da...

Humana ( HUM ) had a pretty decent 2019 as its stock rallied over 30 percent, delivering solid returns to investors. I don't generally cover non-pharma stocks, but this rally, coupled with some interesting news lately, has made HUM an interesting stock to watch. While the company made stride...

FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor Grachev as...

aTyr Pharma (NASDAQ: LIFE ) +63%  on Kyorin Pharma deal . More news on: aTyr Pharma, Inc., Town Sports International Holdings, Inc., Pulmatrix, Inc., Stocks on the move, Read more ...

Thinly traded nano cap Cellectar Biosciences (NASDAQ: CLRB ) perks up  11%  premarket on average volume in reaction to Orphan Drug designation in the U.S. for CLR 131 for slow-growing type of non-Hodgkin lymphoma called lymphoplasmacytic lymphoma (LPL). More news on: Cellecta...

FLORHAM PARK, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Adm...

Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...

FLORHAM PARK, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president ...